Research programme: diabetes nanoparticle therapeutics - MidaSol Therapeutics

Drug Profile

Research programme: diabetes nanoparticle therapeutics - MidaSol Therapeutics

Alternative Names: GLP-1 - MidaSol; GLP-1/insulin - MidaSol; Midaform™ GLP-1; Midaform™ insulin/GLP-1; PharmFilm®

Latest Information Update: 21 May 2015

Price : $50

At a glance

  • Originator MidaSol Therapeutics
  • Class Glucagon-like peptides; Hormones; Insulins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetes mellitus

Most Recent Events

  • 06 Mar 2015 MidaSol and an unnamed global pharmaceutical company agree to co-develop nanoparticle therapeutics in United Kingdom for Diabetes mellitus
  • 15 Nov 2011 Swissmedic approves IND application for Insulin nanoparticles in Diabetes mellitus
  • 05 Jan 2011 MonoSol Rx and Midatech complete a preclinical study in primate diabetes model
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top